Zymeworks (NYSE:ZYME) is a biotherapeutics company focused on the development and commercialization of next-generation multifunctional biotherapeutics, designed to improve patient outcomes in cancer and autoimmune diseases. The company is versatile in its approach, engaging in the discovery, development, and commercialization of innovative protein-based therapeutics. Zymeworks' projects center around its proprietary platforms which enhance the efficacy and safety of therapeutic antibodies and antibody-drug conjugates. A key objective for Zymeworks is to advance its pipeline of preclinical and clinical candidates, with the ultimate goal of delivering groundbreaking treatments to patients in need.